- Home
- TPR vs BIIB Comparison
TPR vs BIIB Comparison
Compare TPR & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPR
- BIIB
- Stock Information
- Founded
- TPR 1941
- BIIB 1978
- Country
- TPR United States
- BIIB United States
- Employees
- TPR N/A
- BIIB N/A
- Industry
- TPR Apparel
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- TPR Consumer Discretionary
- BIIB Health Care
- Exchange
- TPR Nasdaq
- BIIB Nasdaq
- Market Cap
- TPR 16.8B
- BIIB 19.9B
- IPO Year
- TPR 2000
- BIIB 1991
- Fundamental
- Price
- TPR $77.54
- BIIB $119.39
- Analyst Decision
- TPR Buy
- BIIB Buy
- Analyst Count
- TPR 18
- BIIB 27
- Target Price
- TPR $80.17
- BIIB $201.26
- AVG Volume (30 Days)
- TPR 5.0M
- BIIB 1.5M
- Earning Date
- TPR 05-08-2025
- BIIB 05-01-2025
- Dividend Yield
- TPR 1.81%
- BIIB N/A
- EPS Growth
- TPR 0.55
- BIIB 26.39
- EPS
- TPR 3.79
- BIIB 10.12
- Revenue
- TPR $6,878,600,000.00
- BIIB $9,816,400,000.00
- Revenue This Year
- TPR $4.07
- BIIB N/A
- Revenue Next Year
- TPR $2.78
- BIIB N/A
- P/E Ratio
- TPR $20.46
- BIIB $11.70
- Revenue Growth
- TPR 2.67
- BIIB 1.59
- 52 Week Low
- TPR $35.23
- BIIB $110.04
- 52 Week High
- TPR $90.85
- BIIB $238.00
- Technical
- Relative Strength Index (RSI)
- TPR 71.51
- BIIB 44.51
- Support Level
- TPR $71.99
- BIIB $115.25
- Resistance Level
- TPR $80.99
- BIIB $125.34
- Average True Range (ATR)
- TPR 2.39
- BIIB 3.39
- MACD
- TPR 1.41
- BIIB 0.72
- Stochastic Oscillator
- TPR 85.43
- BIIB 41.03
About TPR Tapestry Inc.
Coach, Kate Spade, and Stuart Weitzman are New York City-based Tapestry's fashion and accessory brands. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (64% of fiscal 2024 sales), Europe, Asia, and elsewhere. Coach (76% of sales) is best known for affordable luxury leather products. Kate Spade (20%) is known for colorful patterns and graphics. Both Coach and Kate Spade specialize in women's handbags and accessories, 69% of Tapestry's fiscal 2024 sales. Stuart Weitzman (4%) generates virtually all its revenue from women's luxury footwear.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.